Cassava Sciences’ simufilam failed a Phase III trial for Alzheimer’s disease, likely marking the end of a drug surrounded by allegations of poorly done and fraudulent research.
A Controversial Alzheimer’s Drug Has Gone Down in Flames
Related Posts
The only thing more attractive to 5th graders than snow…
This story was originally published by Grist. You can subscribe…
Famines, sea level rise, extreme weather, more pandemics—by this point,…